Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥183.06 million, representing a 13.06% increase compared to ¥161.91 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was approximately -¥20.67 million, a decrease of 486.37% from a profit of ¥5.35 million in the same period last year[19]. - The basic earnings per share for the first half of 2023 was -¥0.03, down 528.57% from ¥0.007 in the same period last year[19]. - The weighted average return on equity decreased to -6.49%, down 7.10 percentage points from 0.61% in the same period last year[19]. - The net cash flow from operating activities for the first half of 2023 was approximately ¥28.34 million, a decrease of 31.70% from ¥41.50 million in the same period last year[19]. - The total assets at the end of the reporting period were approximately ¥819.53 million, a decrease of 7.38% from ¥884.83 million at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥308.37 million, down 6.28% from ¥329.05 million at the end of the previous year[19]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of approximately -¥23.92 million compared to a profit of ¥5.61 million in the same period last year, a decrease of 526.50%[19]. Market and Industry Insights - The health supplement market in China reached a scale of over 690 billion in 2022, showing a year-on-year growth of 12% from 2021[28]. - By 2028, the Chinese health supplement market is projected to exceed 1.5 trillion, driven by increasing consumer awareness and demand for health products[29]. - The health supplement industry is expected to benefit from the aging population and rising disposable incomes, leading to a more rigid demand for health products[27]. Business Operations - The company operates six self-managed profit-oriented elderly care institutions, providing medical, rehabilitation, and nursing services[31]. - The company's sales model has shifted to focus primarily on online platforms, with successful operations on major e-commerce sites like JD.com and Tmall[27]. - The company's main business includes the research, production, and sales of health supplements and raw materials[24]. - The health supplement production process is based on sales forecasts provided by the marketing department, ensuring alignment with market demand[25]. - The company has adjusted its sales channels to prioritize online sales due to the decline of traditional offline retail[26]. - The elderly care segment includes management consulting services for non-profit hospitals and nursing homes, expanding the company's service offerings[31]. Financial Management - The company has a strong cost control capability, utilizing a three-tiered responsibility analysis system to optimize operational costs[36]. - The operating cost increased to CNY 110,178,847.04, up by 4.58% from CNY 105,355,824.71 year-on-year[41]. - Sales expenses surged by 35.28% to CNY 19,539,041.69, primarily due to increased salary expenditures compared to the previous period[42]. - Research and development expenses decreased by 30.56% to CNY 5,181,181.87, indicating reduced investment in R&D activities[41]. - The company reported a significant increase in financial expenses, which rose by 131.69% to CNY 4,950,927.00, reflecting higher borrowing costs[41]. Regulatory and Compliance Issues - The company has acknowledged the existence of non-operating fund occupation by controlling shareholders and other related parties[7]. - The report includes a risk statement regarding potential risks associated with forward-looking statements, urging investors to be cautious[6]. - The company is experiencing increased regulatory scrutiny in the health supplement industry, which may impact innovation and product development timelines[52]. - The reliance on medical insurance and long-term care insurance for revenue poses a risk due to potential policy changes affecting operational stability[54]. - The healthcare industry faces rising labor costs, which constitute a significant portion of total operating costs due to increasing wage levels and social security contributions[55]. Management Changes - Changes in the board included the appointment of Zhu Yingzheng as the new president, effective from April 2023[65]. - The company faced management changes with several resignations, including the departure of Vice President Hua Yuming and others due to personal reasons[64]. - The company’s eighth supervisory board elected new supervisors, Li Jiaru and Zhang Shun, on August 23, 2023[65]. - The company is focused on maintaining compliance with corporate governance standards amid ongoing management transitions[61]. Shareholder Information - The total number of ordinary shareholders reached 31,624 by the end of the reporting period[96]. - The total number of shares decreased from 780,000,000 to 774,920,000 due to the cancellation of 5,080,000 repurchased shares[93][94]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., holds 112,184,187 shares, representing 14.48% of the total[98]. - The second-largest shareholder, Shanghai Yunjian Industrial Development Co., Ltd., holds 82,362,600 shares, accounting for 10.63%[98]. Audit and Financial Reporting - The company received a qualified audit opinion for the 2022 financial statements, primarily due to issues related to asset impairment losses totaling CNY 361 million and CNY 20 million for specific investments[78]. - The audited 2022 annual report was disclosed on August 31, 2023, with a qualified audit opinion issued by Shandong Shuntian Xincheng Accounting Firm[85]. - The company is implementing targeted measures to improve information disclosure and compliance following the reprimand from the Shanghai Stock Exchange[83]. Corporate Governance - The company is committed to improving corporate governance and internal controls to mitigate risks and ensure sustainable development[79]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2023, with no dividends or stock bonuses issued[67]. Investment and Development - The company is actively pursuing new product development and marketing strategies, including a new logo and packaging to enhance product functionality and quality[37]. - The company plans to focus on market expansion and new product development in the upcoming quarters[107].

Financial Performance - The company reported a net profit of -35,889,317.58 yuan for the fiscal year 2022, with no earnings reserve provision made[9]. - The total distributable profit for the parent company stands at 179,203,831.03 yuan, but no profit distribution or capital reserve increase is proposed due to overall performance losses[9]. - The company's operating revenue for 2022 was approximately ¥377.15 million, representing a 4.02% increase compared to ¥362.58 million in 2021[25]. - The net profit attributable to shareholders for 2022 was approximately -¥498.42 million, a significant decline from a profit of ¥37.18 million in 2021, marking a decrease of 5,490.38%[25]. - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately -¥501.97 million in 2022, compared to -¥20.76 million in 2021, reflecting a decrease of 2,317.70%[25]. - The net cash flow from operating activities for 2022 was approximately ¥98.27 million, down 5.57% from ¥104.06 million in 2021[25]. - The total assets at the end of 2022 were approximately ¥884.83 million, a decrease of 34.35% from ¥1.35 billion at the end of 2021[25]. - The net assets attributable to shareholders decreased by 60.19% to approximately ¥329.05 million at the end of 2022, down from ¥826.62 million at the end of 2021[25]. - The basic earnings per share for 2022 was -¥0.64, compared to -¥0.01 in 2021, indicating a significant decline[27]. - The weighted average return on equity decreased by 85.18 percentage points to -86.26% in 2022, down from 11.30% in 2021[27]. Audit and Compliance - The audit report issued by Shandong Shuntian Xincheng Accounting Firm contains a qualified opinion, highlighting concerns over the accuracy of financial data[7]. - The company has not yet implemented recommendations from the audit committee to hire an authoritative institution for further evaluation of accounting errors[5]. - The company received a qualified audit opinion from Shandong Shuntian Xincheng Accounting Firm for the 2022 financial statements, issued on August 29, 2023[179]. - The audit committee expressed concerns regarding the frequent change of the annual audit firm, which could negatively impact the company's operations and development[145]. - The audit report highlighted that the matters leading to the qualified opinion do not affect the overall fairness of the financial statements[188]. Asset Management and Impairment - The company faced significant accounting errors and asset impairment issues, including a 36,100,000 yuan impairment on other current assets and a 20,000,000 yuan impairment on long-term equity investments[5]. - The company reported a significant asset impairment loss of RMB 518.63 million, indicating challenges in its financial health[52]. - The company fully recognized an asset impairment loss on "other non-current assets - operating income rights" valued at RMB 36,100,000[183]. - The company adjusted the accounting treatment for a previous investment and recognized an impairment provision of RMB 20,000,000 for the investment in Huigu Shangrao[184]. Market and Business Strategy - The company focused on its core health business, optimizing channel structures and reducing operational costs in the health supplement segment[35]. - In 2022, the company achieved significant progress in the raw materials business, particularly in the US and Southeast Asia markets, while maintaining stable sales management[36]. - The health supplement market in China is expected to grow at a rate of at least 4% annually over the next five years, reaching a market size of approximately 517.8 billion yuan by 2026[41]. - The aging population in China is driving demand for medical care services, with increasing competition for institutions providing specialized clinical care[42]. - The company aims to transform health supplements from luxury items to essential dietary nutrition products in response to rising consumer health awareness[41]. - The company is actively exploring new media advertising formats and integrated marketing strategies to enhance brand visibility and customer engagement[36]. Governance and Management - The company has established a clear governance structure that complies with relevant laws and regulations, ensuring effective decision-making and accountability[98]. - The board of directors consists of 11 members, including 4 independent directors, ensuring compliance with legal requirements and active participation in governance[101]. - The company has implemented a performance evaluation system linking executive compensation to business performance, promoting transparency in management[103]. - The company has established an independent human resources management department, separate from the controlling shareholder, ensuring proper personnel and compensation management[108]. - The company has undergone significant changes in its board, with multiple directors and supervisors being elected or appointed, including the election of new independent directors[130][131]. Employee and Operational Management - The total number of employees in the parent company and major subsidiaries is 968, with 170 in the parent company and 798 in subsidiaries[152]. - The company has established a performance evaluation mechanism for senior management, linking their compensation to the completion of annual business objectives[161]. - The company has implemented a comprehensive training plan for employees, focusing on skills development across various departments[155]. - The company emphasizes fair and reasonable salary standards based on market conditions and job responsibilities[154]. Risks and Challenges - The company is currently under scrutiny for potential non-operating fund occupation by controlling shareholders[11]. - There are risks associated with future development strategies as outlined in the management discussion and analysis section of the report[11]. - The company faces policy risks in the health supplement industry due to increased regulatory scrutiny, including revisions to laws and new management measures[94]. - In the medical care industry, the company is significantly reliant on insurance payments, making it vulnerable to policy changes affecting operations[95]. - Rising labor costs pose a risk to the company's operations in the labor-intensive medical care sector[95]. Research and Development - The company increased its R&D efforts, developing new products and improving existing ones, including a new process for monk fruit juice and enhancements in tea amino acid projects[36]. - The company has established partnerships with institutions like Shanghai Jiao Tong University for R&D, focusing on probiotics and functional food technologies[77]. - The company has received multiple approvals for domestic health products, indicating a strong pipeline for future product launches[78]. - The company has a total of 59 R&D personnel, accounting for 34.71% of the total workforce[67]. Financial Management - The company has a cash dividend policy in place, adhering to relevant regulations and ensuring transparency in decision-making processes[159]. - The total remuneration for all directors, supervisors, and senior management for the year amounted to 5.0191 million (pre-tax)[129]. - The company reported a total revenue of 30,000 million in the latest financial year, maintaining a stable performance compared to previous periods[114]. - The company has a robust cost control system, analyzing operational costs at multiple levels to maintain competitive advantages[50].

上海交大昂立股份有限公司 关于公司董事、独立董事辞职的公告 证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-084 刘峰先生因担任上市公司独立董事超过 3 家，根据《上市公司独立董事管理办法》 之要求对照，申请辞去公司第八届董事会董事、董事会提名委员会主任委员、战略委员 会委员、薪酬与考核委员会委员职务。 李柏龄先生因担任境内上市公司独立董事已超过 3 家，根据中国证监会发布的《上 市公司独立董事管理办法》之精神，申请辞去公司第八届董事会董事、董事会审计委员 会主任委员职务。 因独立董事刘峰先生、李柏龄先生的辞职会导致独立董事人数少于现任董事会成员 比例的三分之一，经过协商，李柏龄先生将继续履职至股东大会选举产生新任独立董事 止。上述董事、独立董事的辞职不会影响公司董事会及本公司的正常运作，公司将按照 有关规定尽快完成董事、独立董事的补选工作。 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海交大昂立股份有限公司（以下简称"公司"）董事会于 2023 年 8 月 28 日收到 董事赵思渊女士、唐道清 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-083 上海交大昂立股份有限公司 关于公司股票可能被终止上市的第八次风险提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海交大昂立股份有限公司（以下简称"公司"）于8月23日召开公司2023年 第四次临时股东大会，审议通过了聘任山东舜天信诚会计师事务所（特殊普通合伙） 为公司2022年度年报审计机构。公司目前正全力配合会计师事务所进行相关年报审计 工作，公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错 更正事项，如公司未在9月4日内披露经审计的2022年年度报告，公司股票将被终止上 市。 ● 若公司2022年度财务会计报告被出具无法表示意见或否定意见的审计报告，公 司股票将继续被实施退市风险警示。 ● 根据《股票上市规则》相关规定，若公司股票在2023年8月31日不能按时披露 2023年半年度报告，公司股票将自前述期限届满的次一交易日起停牌。 ● 公司于2023年5月12日收到中国证券监督管理委员会《立 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-081 上海交大昂立股份有限公司 关于公司股票可能被终止上市的第七次风险提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海交大昂立股份有限公司（以下简称"公司"）聘任2022年度年报审计机构 事项尚需经公司2023年第四次临时股东大会审议通过，该会议定于8月23日召开。根据 《股票上市规则》相关规定，上市公司聘请或者解聘会计师事务所必须由股东大会决 定，董事会不得在股东大会决定前委托会计师事务所开展工作。如公司未在9月4日内 披露经审计的2022年年度报告，公司股票将被终止上市。 ● 公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错 更正事项，仍存在可能无法按时披露经审计的2022年年度报告的风险。 ● 若公司2022年度财务会计报告被出具无法表示意见或否定意见的审计报告，公 司股票将继续被实施退市风险警示。 ● 根据《股票上市规则》相关规定，若公司股票在2023年8月31日不能按时披露 2023年半年 ...

| | 目 录 | | --- | --- | | 一、2023 | 年第四次临时股东大会会议议程······································1 | | 二、2023 | 年第四次临时股东大会须知··········································2 | | | 三、审议本次股东大会议案··················································4 | | | 1、关于聘任山东舜天信诚会计师事务所（特殊普通合伙）的议案···············4 | | | 2、关于选举李家儒先生为公司第八届监事会监事的议案·····················6 | | | 3、关于选举张顺先生为公司第八届监事会监事的议案·······················7 | 上海交大昂立股份有限公司 2023 年第四次临时股东大会会议议程 上海交大昂立股份有限公司 2023 年第四次临时股东大会 会议资料 $$\exists{0}\Longleftarrow\exists{\nleftarrow}{J}\back ...

● 根据《股票上市规则》第9.4.6条规定，在公司股票被实施退市风险警示期 间，应当每5个交易日披露1次风险提示公告，提示公司股票可能终止上市的风险。 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海交大昂立股份有限公司（以下简称"公司"）聘任2022年度年报审计机构 事项尚需经公司2023年第四次临时股东大会审议通过，该会议定于8月23日召开。根据 《股票上市规则》相关规定，上市公司聘请或者解聘会计师事务所必须由股东大会决 定，董事会不得在股东大会决定前委托会计师事务所开展工作。如公司未在9月4日内 披露经审计的2022年年度报告，公司股票将被终止上市。 ● 公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错 更正事项，仍存在可能无法按时披露经审计的2022年年度报告的风险。 ● 若公司2022年度财务会计报告被出具无法表示意见或否定意见的审计报告，公 司股票将继续被实施退市风险警示。 证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-080 上海交大昂立股份有 ...

关于《上海交大昂立股份有限公司 股票交易异常波动问询函》的回函 上海交大昂立股份有限公司: 本公司及其一致行动人于 2023年8月11 日收到贵公司发来的《上海交大昂 立股份有限公司关于股票交易异常波动的问询函》,经本公司及其一致行动人认 真自查核实,现将有关问题回复如下: 一、截至目前,本公司不存在涉及上海交大昂立股份有限公司(以下简称"交 大昂立")应披露而未披露的重大信息。 二、截至目前,本公司不存在处于筹划阶段的涉及交大昂立的重大事项,包 括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、 资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者等 重大事项。 三、在本次股票交易异常波动期间,本公司不存在买卖交大昂立股票的情形。 特此回复。 上海饰杰装饰设计工程 f创科技发展合伙企业(有限合 丽水农帮咨询合伙企业 一、截至目前,本人不存在涉及上海交大昂立股份有限公司(以下简称"交 大昂立"）应披露而未披露的重大信息。 二、截至目前,本人不存在处于筹划阶段的涉及交大昂立的重大事项,包括 但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、资 产注入、股份回 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-079 上海交大昂立股份有限公司 关于公司股票交易异常波动暨风险提示的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 经公司自查，公司目前生产经营活动一切正常，市场环境、行业政策没有发生重 大调整、生产成本和销售等情况没有出现大幅波动、内部生产经营秩序正常。 ● 经公司自查及书面发函询问控股股东、实际控制人，截止本公告披露日，无应 披露而未披露的重大事项。 ● 公司聘任2022年度年报审计机构事项尚需经公司2023年第四次临时股东大会审 议通过，该会议定于8月23日召开。根据《股票上市规则》相关规定，上市公司聘请或 者解聘会计师事务所必须由股东大会决定，董事会不得在股东大会决定前委托会计师 事务所开展工作。如公司未在9月4日内披露经审计的2022年年度报告，公司股票将被 终止上市。 ● 公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错 更正事项，仍存在可能无法按时披露经审计的2022年年度报告的风险。 ● 若公司2 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-078 上海交大昂立股份有限公司 关于公司股票交易风险提示公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 公司聘任 2022 年度年报审计机构事项尚需经公司 2023 年第四次临时股东大会 审议通过，该会议定于 8 月 23 日召开。根据《股票上市规则》相关规定，上市公司聘 请或者解聘会计师事务所必须由股东大会决定，董事会不得在股东大会决定前委托会计 师事务所开展工作。如公司未在 9 月 4 日内披露经审计的 2022 年年度报告，公司股票 将被终止上市。 ● 公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错更 正事项，仍存在可能无法按时披露经审计的 2022 年年度报告的风险。 ● 若公司 2022 年度财务会计报告被出具无法表示意见或否定意见的审计报告，公 司股票将继续被实施退市风险警示。 一、二级市场交易风险提示 截至2023年8月10日，公司股票收盘价为2.21元/股。公司股票于2023年8月9日触 及 ...